Technology Insight: imaging neurodegeneration in Parkinson's disease
暂无分享,去创建一个
[1] C. Summerfield,et al. Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia , 2005, Journal of Neurology.
[2] Clinical and [ 18 F ] dopa PET findings in early Parkinson ' s disease , .
[3] David J Brooks,et al. Plasticity of the nigropallidal pathway in Parkinson's disease , 2003, Annals of neurology.
[4] Nora Turjanski,et al. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. , 2005, Brain : a journal of neurology.
[5] Andrew J Lees,et al. Diffusion‐weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple‐system atrophy from progressive supranuclear palsy , 2007, Movement disorders : official journal of the Movement Disorder Society.
[6] L. Deecke,et al. [123I]β‐CIT spect in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration , 2000, Movement disorders : official journal of the Movement Disorder Society.
[7] D R Rajput,et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease. , 1993, Journal of neurology, neurosurgery, and psychiatry.
[8] David Eidelberg,et al. Regional metabolic changes in Parkinsonian patients with normal dopaminergic imaging , 2007, Movement disorders : official journal of the Movement Disorder Society.
[9] W. A. White. Stages of Development. , 1919 .
[10] T. Ishikawa,et al. The Metabolic Topography of Parkinsonism , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[11] Nicola Pavese,et al. Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. , 2002, Brain : a journal of neurology.
[12] D J Burn,et al. Dopaminergic function in familial Parkinson's disease: A clinical and 18F‐dopa positron emission tomography study , 1997, Annals of neurology.
[13] M. Skalej,et al. Magnetic resonance imaging–based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy , 1999, Annals of neurology.
[14] L. Minati,et al. Imaging degeneration of the substantia nigra in Parkinson disease with inversion-recovery MR imaging. , 2007, AJNR. American journal of neuroradiology.
[15] I. McKeith,et al. Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging , 2005, Movement disorders : official journal of the Movement Disorder Society.
[16] V. Dhawan,et al. Metabolic correlates of levodopa response in Parkinson’s disease , 2001, Neurology.
[17] R. Hilker,et al. Dementia in Parkinson disease , 2005, Neurology.
[18] Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation , 2005, Neurology.
[19] A. Lees,et al. Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.
[20] D J Brooks,et al. Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. , 1994, Journal of neurology, neurosurgery, and psychiatry.
[21] S. Minoshima,et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease , 1996, Annals of neurology.
[22] J. Hughes,et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[23] J. Hogg. Magnetic resonance imaging. , 1994, Journal of the Royal Naval Medical Service.
[24] N. Bohnen,et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. , 2003, Archives of neurology.
[25] D. Brooks,et al. Extrastriatal monoamine neuron function in Parkinson’s disease: An 18F-dopa PET study , 2008, Neurobiology of Disease.
[26] D J Brooks,et al. Clinical and [18F] dopa PET findings in early Parkinson's disease. , 1995, Journal of neurology, neurosurgery, and psychiatry.
[27] G Becker,et al. Relationship of substantia nigra echogenicity and motor function in elderly subjects , 2001, Neurology.
[28] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[29] Makoto Sawada,et al. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains , 2003, Acta Neuropathologica.
[30] Jan Booij,et al. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism , 2001, European Journal of Nuclear Medicine.
[31] Nick C Fox,et al. Regional brain volumes distinguish PSP, MSA‐P, and PD: MRI‐based clinico‐radiological correlations , 2006, Movement disorders : official journal of the Movement Disorder Society.
[32] Christine Klein,et al. Brain parenchyma sonography detects preclinical parkinsonism , 2004, Movement disorders : official journal of the Movement Disorder Society.
[33] Zuzana Walker. Dementia with Lewy bodies , 2001 .
[34] I. McKeith,et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.
[35] Won Yong Lee,et al. Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[36] D. Brooks. Functional imaging in relation to parkinsonian syndromes , 1993, Journal of the Neurological Sciences.
[37] E. Tolosa,et al. Impact of dopamine transporter SPECT using 123I‐Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes , 2004, Movement disorders : official journal of the Movement Disorder Society.
[38] N. Bohnen,et al. Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease , 2005, Neuroscience Letters.
[39] Daniela Berg,et al. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings , 2001, Journal of Neurology.
[40] D E Kuhl,et al. Motor correlates of occipital glucose hypometabolism in Parkinson’s disease without dementia , 1999, Neurology.
[41] L. Golbe. The genetics of Parkinson's disease: A reconsideration , 1990, Neurology.
[42] Akinori Nakamura,et al. Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study. , 2002, Brain : a journal of neurology.
[43] H. Berendse,et al. Idiopathic hyposmia as a preclinical sign of Parkinson's disease , 2004, Annals of neurology.
[44] Anna Barnes,et al. FDG PET in the differential diagnosis of parkinsonian disorders , 2005, NeuroImage.
[45] J R Moeller,et al. Metabolic changes following subthalamotomy for advanced Parkinson's disease , 2001, Annals of neurology.
[46] V J Cunningham,et al. Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study. , 2000, Brain : a journal of neurology.
[47] David J. Brooks,et al. A comparison of 18F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson’s disease , 2001, Neurology.
[48] Z Walker,et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand , 2002, Journal of neurology, neurosurgery, and psychiatry.
[49] J O Rinne,et al. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. , 2000, Archives of neurology.
[50] Klaus Fassbender,et al. Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease. , 2006, Brain : a journal of neurology.
[51] D. Brooks,et al. Tremor in Parkinson’s disease and serotonergic dysfunction , 2003, Neurology.
[52] W. Oertel,et al. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. , 2004, Brain : a journal of neurology.
[53] J. Patterson,et al. Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging , 2006, Nuclear medicine communications.
[54] Thomas Hummel,et al. Detection of presymptomatic Parkinson's disease: Combining smell tests, transcranial sonography, and SPECT , 2004, Movement disorders : official journal of the Movement Disorder Society.
[55] Hansjürgen Bratzke,et al. Stages in the development of Parkinson’s disease-related pathology , 2004, Cell and Tissue Research.
[56] Nick C Fox,et al. Amyloid, hypometabolism, and cognition in Alzheimer disease , 2007, Neurology.
[57] T Turner,et al. Structural changes. , 1991, Nursing times.
[58] Vesna Sossi,et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. , 2005, Brain : a journal of neurology.
[59] N. Mauras. Growth Hormone Therapy in the Glucocorticosteroid-Dependent Child: Metabolic and Linear Growth Effects , 2002, Hormone Research in Paediatrics.
[60] D Oakes,et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease , 2003, Experimental Neurology.
[61] E. Yoshikawa,et al. Microglial activation and dopamine terminal loss in early Parkinson's disease , 2005, Annals of neurology.
[62] E. Tolosa,et al. Role of DAT‐SPECT in the diagnostic work up of Parkinsonism , 2007 .
[63] S. Gacinovic,et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]‐FP‐CIT SPECT imaging: The [123I]‐FP‐CIT study group , 2000, Movement disorders : official journal of the Movement Disorder Society.
[64] Francesco Fera,et al. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. , 2006, Brain : a journal of neurology.
[65] C. Rowe,et al. II.P13 Amyloid load in Parkinson's Disease Dementia (PDD) and Lewy Body Dementia (LBD) measured with 11C-PIB PET , 2006 .
[66] C. Summerfield,et al. Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. , 2005, Archives of neurology.
[67] Nicola Pavese,et al. Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. , 2004, Brain : a journal of neurology.
[68] M Hutchinson,et al. Structural changes of the substantia nigra in Parkinson's disease as revealed by MR imaging. , 2000, AJNR. American journal of neuroradiology.
[69] Daniela Berg,et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. , 2002, Archives of neurology.
[70] C Kremser,et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy , 2003, Neurology.
[71] Karl Herholz,et al. The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans , 2002, Neuroscience Letters.
[72] K. Uğurbil,et al. Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts , 2007, Movement disorders : official journal of the Movement Disorder Society.
[73] Chi-Shing Zee,et al. Magnetic Resonance Imaging-Based Volumetric Analysis of Basal Ganglia Nuclei and Substantia Nigra in Patients with Parkinson’s Disease , 2006, Neurosurgery.
[74] A. Lees,et al. What features improve the accuracy of clinical diagnosis in Parkinson's disease , 1992, Neurology.
[75] I. McKeith,et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease , 2004, Neurology.
[76] P. Amarenco,et al. Tremor in Parkinson's disease and serotonergic dysfunction An 11 C-WAY 100635 PET study , 2003 .
[77] David Oakes,et al. (123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. , 2004, Archives of neurology.
[78] Daniela Berg,et al. Five‐year follow‐up study of hyperechogenicity of the substantia nigra in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.